Corona vaccination for 5-11 year olds possible this year

22.9.2021

In March 2021, BioNTech SE and Pfizer began a I/II/III-phase study with healthy children under the age of 12 with three different doses (30 µg, 20 µg and 10 µg) in three different age groups (6 months - 2 years old, 2 - 5 years old, and 5 - 12 years old). In a press release, BioNTech emphasized the good tolerability of the COVID-19 vaccine Comirnaty® in children 5 11 years of age. The active ingredient shows a good safety profile and leads to the formation of robust amounts of neutralising antibodies. According to BioNTech, the relevant study results are available and only need to be prepared for the approval authorities. They want to submit the data as soon as possible to the FDA, EMA and other regulatory authorities worldwide. The data for children under 5 years old is expected towards the end of 2021. Moderna has also been conducting a study for the approval of its vaccine Spikevax® for children under the age of 12 since March 2021 and plans to complete studies with its vaccine in children under 12 this year. Parents and doctors should wait for the approvals, according to the President of the German Society for Child and Adolescent Medicine (Deutsche Gesellschaft für Kinder- und Jugendmedizin), Professor Dr. Jörg Dötsch from Cologne University Hospital. He advises against off-label use for children under 12. This also applies to children at high risk of a severe course of the disease.